Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
RegulatoryapprovedVEPPANUPositive
AI Analysis
Summary
Rigel Pharmaceuticals announced the availability of VEPPANU (vepdegestrant) for patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, marking a regulatory approval and commercial launch of the drug.
Outcome Details
Drug availability announced for patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Importance:8/10
Sentiment:
0.80
FDA ApprovalBreast CancerCommercial LaunchOncology
Related Companies
Read the original article
Published by yahoo_finance on August 13, 2026 12:05 PM